[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
October 2005

COMMENTS AND OPINIONS

Arch Dermatol. 2005;141(10):1320-1321. doi:10.1001/archderm.141.10.1320

We have found that a 5% lidocaine patch (Lidoderm; Endo Pharmaceuticals Inc, Chadds Ford, Pa) is helpful as both first-line and adjunctive treatment for managing the pain of erythromelalgia. (Lidoderm is manufactured by Teikoku Seiyaku Co Ltd, Sanbonmatsu, Kagawa, Japan, for Endo Pharmaceuticals and is a registered trademark of Hind Health Care, Inc, San Jose, Calif.) This form of topical lidocaine has been approved by the US Food and Drug Administration for the relief of pain associated with postherpetic neuralgia.1 We previously reported our experience with this patch in treating a young woman who was disabled because of her erythromelalgia.2 Her pain has been controlled with the topical lidocaine patch for 3 years, and she continues to use the lidocaine patch as the sole intervention for erythromelalgia.

First Page Preview View Large
First page PDF preview
First page PDF preview
×